الفهرس 
HCV Related kidney diseasesOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Background: Hepatitis C virus (HCV) infection is known to be associated with high rates of liver related morbidities and mortality in the whole world. The interest of Public in HCV is growing, as more than 180 million people, (2.8%) of the global population, are infected with HCV.
Aim of the Study: To evaluate the effect of direct antiviral agents on glomerular filtrating rate (GFR).
Patients and Methods: The study performed on 120 subjects from the Hepatology outpatient clinic at Sharque elmadinah Hospital in Alexandria.
Results: The current results showed that the mean decrease in GFR in patients who received SOF/DAC were 5.21 ± 15.57 and 6.18 ± 16.13 after full 12 week regimen and after 1 year respectively while the mean decrease in patients SOF/SIM were 4.35 ± 14.9 and 3.57 ± 13.08 respectively. The decrease was not statistically significant in both regimens. Moreover, the mean GFR decrease in the only patient received SOF/Ribavirin was 12.8 and 30.9 after 12 weeks regimen and after one year respectively while for the only patient who received PAR/OMB/Rito/Ribavirin the decrease was 5.5 and 53.4 respectively. unfortunately, due to lack of sufficient patients number, the decrease an not be expressed statistically.
Conclusion: The new direct antiviral agents (sofosbuvir , daclatasvir and simeprevir ) are effective and safe regarding glomerular filtration rate in patients with normal renal function. However, a meticulous monitoring of kidney function is mandatory during the course of these medications to early detect any untoward side effects. Moreover, such studies will yield beneficial data about the renal safety of these drugs if it could be performed on a larger scale of patients.